MasTec (NYSE:MTZ) reported fourth-quarter and full-year 2025 results that management said exceeded its guidance for revenue, adjusted EBITDA and adjusted earnings per share, supported by organic ...
Iovance Biotherapeutics reported early clinical trial data for lifileucel in advanced soft tissue sarcomas, showing promising efficacy signals. The company also received FDA Fast Track designation for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results